Literature DB >> 8963435

Comparative patch-clamp studies with freshly dissociated rat hippocampal and striatal neurons on the NMDA receptor antagonistic effects of amantadine and memantine.

C G Parsons1, V A Panchenko, V O Pinchenko, A Y Tsyndrenko, O A Krishtal.   

Abstract

Patch- and concentration-clamp techniques were used to compare the effects of the uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonists (+)-MK-801 (dizocilpine, (+)-5-methyl-10, 11-dihydro-5H-dibenzocyclohepten-5, 10-imine maleate), ketamine, memantine (1-amino-3,5-dimethyladamantane) and amantadine (1-amino-adamantane) on agonist-induced inward currents in freshly dissociated rat hippocampal and striatal neurons. In hippocampal neurons, ketamine (5 microM), menantine (10 microM) and amantadine (100 microM) selectively antagonized inward current responses to NMDA (500 microM plus glycine 5 microM) in a voltage-dependent manner without affecting responses to (s)-alpha-amino-3-hydroxy-5-methyl-4-isoxazoleproprionic acid (100 microM) or gamma-aminobutyric acid (10 microM). The NMDA receptor antagonistic effect of all four agents was typical of open channel blockade. The kinetics of blockade/unblockade was inversely related to antagonist affinity. In hippocampal neurons amantadine was the least potent NMDA receptor antagonist (IC50 18.6 +/- 0.9 microM) and showed the fastest blocking kinetics, whereas (+)-MK-801 was the most potent (IC50 0.12 +/- 0.01 microM) and showed the slowest blocking kinetics. Memantine (IC50 1.04 +/- 0.26 microM) and ketamine (IC50 0.43 +/- 0.10 microM) were almost equipotent and had similar, intermediate blocking kinetics. In striatal neurons recorded under identical conditions (+)-MK-801, ketamine and memantine were 3- to 4-fold less potent whereas amantadine was somewhat more potent than on hippocampal neurons. This could offer an explanation for the better clinical profile of amantadine in Parkinson's disease, as therapeutically relevant concentrations of amantadine are likely to be more active in the striatum whereas memantine is likely to be more active in other structures.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8963435     DOI: 10.1111/j.1460-9568.1996.tb01228.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  29 in total

1.  Volatile anesthetics block actin-based motility in dendritic spines.

Authors:  S Kaech; H Brinkhaus; A Matus
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-31       Impact factor: 11.205

2.  Studies of the structure of glutamate receptor ion channels and the mechanisms of their blockade by organic cations.

Authors:  L G Magazanik; D B Tikhonov; K V Bol'shakov; V E Gmiro; S L Buldakova; M V Samoilova
Journal:  Neurosci Behav Physiol       Date:  2003-03

3.  The neuroprotectant properties of glutamate antagonists and antiglutamatergic drugs.

Authors:  V Pedersen; W J Schmidt
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

4.  Effects of Mg2+ on recovery of NMDA receptors from inhibition by memantine and ketamine reveal properties of a second site.

Authors:  Nathan G Glasgow; Madeleine R Wilcox; Jon W Johnson
Journal:  Neuropharmacology       Date:  2018-05-12       Impact factor: 5.250

5.  Co-administration of memantine and amantadine with sub/suprathreshold doses of L-Dopa restores motor behaviour of MPTP-treated mice.

Authors:  A Fredriksson; W Danysz; G Quack; T Archer
Journal:  J Neural Transm (Vienna)       Date:  2001       Impact factor: 3.575

Review 6.  The lipophilic bullet hits the targets: medicinal chemistry of adamantane derivatives.

Authors:  Lukas Wanka; Khalid Iqbal; Peter R Schreiner
Journal:  Chem Rev       Date:  2013-02-25       Impact factor: 60.622

Review 7.  Disruption of performance in the five-choice serial reaction time task induced by administration of N-methyl-D-aspartate receptor antagonists: relevance to cognitive dysfunction in schizophrenia.

Authors:  Nurith Amitai; Athina Markou
Journal:  Biol Psychiatry       Date:  2010-05-21       Impact factor: 13.382

8.  Ketamine impairs multiple cognitive domains in rhesus monkeys.

Authors:  Michael A Taffe; Sophia A Davis; Tannia Gutierrez; Lisa H Gold
Journal:  Drug Alcohol Depend       Date:  2002-10-01       Impact factor: 4.492

9.  Pharmacodynamics of memantine: an update.

Authors:  G Rammes; W Danysz; C G Parsons
Journal:  Curr Neuropharmacol       Date:  2008-03       Impact factor: 7.363

10.  Glutamatergic Synaptic Dysfunction and Obsessive-Compulsive Disorder.

Authors:  Jonathan T Ting; Guoping Feng
Journal:  Curr Chem Genomics       Date:  2008-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.